EW posts its Q3 print with the Street the most bullish it has been all year

Edwards Lifesciences reported third-quarter results on the evening of November 4, arriving with the analyst community more aligned to the upside than at any prior point in 2026, and options traders having made the sharpest pivot toward calls in over a month.

The clearest pre-print signal came from the options market. The put/call ratio dropped to 0.86 on November 3, sitting 2.2 standard deviations below its 20-day mean of 1.07. For the entire month of October the ratio held between 1.0 and 1.19. It broke below 0.90 only in the final two sessions before the print, a move that was fast rather than extreme, the 52-week low is 0.75, but notable for its abruptness.

The analyst picture going into the results was equally one-sided. Truist Securities analyst Richard Newitter flipped to Buy from Hold on the morning of November 4, raising his target 18.9% to $113 from $95. That move carried extra weight because Newitter had held his cautious stance since July. It left the consensus at 19 Buys against 6 Holds, with no Sell ratings anywhere on the Street. Barclays had initiated at Overweight with a $110 target in October, and BTIG, UBS and RBC Capital had all maintained Buy-equivalent ratings through the quarter. The mean target of $102.53 sat roughly 8% above Monday's close of $95.19. The debate is not about direction but about margin recovery: the bull case rests on TAVR volume growth and rapid TMTT adoption, while bears point to the adjusted operating margin falling to 23.7% last quarter against a consensus expectation of 25.9%, weighed by elevated SG&A costs.

Short interest offers no particular drama. Positions fell roughly 12% over the past week to 1.48% of the free float, continuing a steady unwind from the mid-October peak near 1.68%. With borrow availability at its maximum and borrowing costs at 0.60% annualised, the lending market is entirely loose. The cost to borrow did jump 63% on the week, but the base is so low that the absolute level remains trivial. The ORTEX short score has drifted down from 31.7 at end of October to 30.5, ranking in the 66th percentile for the sector, consistent with a name that shorts have been quietly exiting rather than building into. This is not a short-interest story.

The stock's performance ahead of the print was itself a data point. EW closed at $95.19 on November 3, up 4.8% on the week. That compared with a median gain of roughly 0.5% across its nearest peers. ISRG fell 1.2% on the week. GMED dropped 1.6%. SYK added 3%. SIBN surged 10.9%, though on its own news. EW's outperformance was not a sector rotation story; it was stock-specific positioning ahead of the print.

Retail attention tracked the same direction. The ORTEX alternative data layer recorded a Wikipedia attention z-score of 2.74 around October 21, the highest reading in recent months, indicating EW was drawing significantly more public interest than its own 90-day average. That is a measure of attention, not a revenue indicator, but it aligned with the broader pre-earnings positioning shift.

The historical pattern on earnings reactions is thin but consistent with moderate moves. The October 2026 print produced a 0.5% next-day gain and a 2.1% five-day gain. The July 2026 print saw the stock fall 2.1% on the day before recovering 3.0% over five days. Neither reaction was dramatic, which fits the low short interest and loose borrow conditions: there is no structural pressure that would amplify a miss.

What matters most now is what management says about the margin trajectory. The Truist upgrade and the broader analyst consensus already price in TAVR growth of 6 to 8% and TMTT revenue of $740 to $780 million for fiscal 2026. The number to watch on the call is the adjusted operating margin guide for Q4 and whether management addresses the SG&A overhang that drove the bear case last quarter.